Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología terapia génica > DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista >

Intratumoural administration of dendritic cells: hostile environment and help by gene therapy
Authors: Huarte, E. (Eduardo)
Tirapu, I. (Íñigo)
Arina, A. (Ainhoa)
Vera, M. (María)
Alfaro, C. (Carlos)
Palencia, B. (Belén)
Busto, V. (Victoria)
Marin, V. (Verónica)
Mazzolini, G. (Guillermo)
Melero, I. (Ignacio)
Keywords: Anticancer
Delivery
Dendritic cells
Gene therapy
Intratumoural administration
Issue Date: 2005
Publisher: Informa Healthcare
Publisher version: http://informahealthcare.com/doi/abs/10.1517/14712598.5.1.7
ISSN: 1744-7682
Citation: Huarte E, Tirapu I, Arina A, Vera M, Alfaro C, Murillo O, et al. Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther 2005 Jan;5(1):7-22.
Abstract
Like paratroopers in special operations, dendritic cells (DCs) can be deployed behind the enemy borders of malignant tissue to ignite an antitumour immune response. 'Cross-priming T cell responses' is the code name for their mission, which consists of taking up antigen from transformed cells or their debris, migrating to lymphoid tissue ferrying the antigenic cargo, and meeting specific T cells. This must be accomplished in such an immunogenic manner that specific T lymphocytes would mount a robust enough response as to fully reject the malignancy. To improve their immunostimulating activity, local gene therapy can be very beneficial, either by transfecting DCs with genes enhancing their performance, or by preparing tumour tissue with pro-inflammatory mediators. In addition, endogenous DCs from the tumour host can be attracted into the malignant tissue following transfection of certain chemokine genes into tumour cells. On their side, tumour stroma and malignant cells set up a hostile immunosuppressive environment for artificially released or attracted DCs. This milieu is usually rich in transforming growth factor-beta, vascular endothelial growth factor, and IL-10, -6 and -8, among other substances that diminish DC performance. Several molecular strategies are being devised to interfere with the immunosuppressive actions of these substances and to further enhance the level of anticancer immunity achieved after artificial release of DCs intratumourally.
Permanent link: http://hdl.handle.net/10171/20418
Appears in Collections:DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista

Files in This Item:

There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.